Intervention Review

You have free access to this content

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB

  1. Surendra K Sharma1,*,
  2. Anju Sharma2,
  3. Tamilarasu Kadhiravan3,
  4. Prathap Tharyan4

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 5 JUL 2013

Assessed as up-to-date: 15 MAY 2013

DOI: 10.1002/14651858.CD007545.pub2


How to Cite

Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD007545. DOI: 10.1002/14651858.CD007545.pub2.

Author Information

  1. 1

    All India Institute of Medical Sciences, Department of Medicine, New Delhi, India

  2. 2

    Indian Council of Medical Research, Division of Publication & Information, New Delhi, India

  3. 3

    Jawaharlal Institute of Postgraduate Medical Education and Research, Department of Medicine, Puducherry, India

  4. 4

    Christian Medical College, South Asian Cochrane Network & Centre, Prof. BV Moses & ICMR Advanced Centre for Research & Training in Evidence Informed Health Care, Vellore, Tamil Nadu, India

*Surendra K Sharma, Department of Medicine, All India Institute of Medical Sciences, Room 3097, Teaching Block, Ansari Nagar, New Delhi, 110029, India. sksharma.aiims@gmail.com. sksharma@aims.ac.in.

Publication History

  1. Publication Status: New
  2. Published Online: 5 JUL 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Rifampicin versus INH, outcome: 1.3 Adherence.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Rifampicin versus INH, outcome: 1.6 Hepatotoxicity.
[Figure 5]
Figure 5. Forest plot of comparison: 3 Rifampicin plus pyrazinamide versus INH, outcome: 3.3 Adherence.
[Figure 6]
Figure 6. Forest plot of comparison: 3 Rifampicin plus pyrazinamide versus INH, outcome: 3.5 Hepatotoxicity.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Rifampicin versus INH, Outcome 1 Active TB.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Rifampicin versus INH, Outcome 2 Drug-resistant TB.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Rifampicin versus INH, Outcome 3 Adherence.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Rifampicin versus INH, Outcome 4 Serious adverse events: (adults with LTBI).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Rifampicin versus INH, Outcome 5 Treatment-limiting adverse events.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Rifampicin versus INH, Outcome 6 Hepatotoxicity.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Rifampicin versus INH, Outcome 7 Gastrointestinal Intolerance.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Rifampicin versus INH, Outcome 8 Rash.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Rifampicin versus INH, Outcome 9 Haematological adverse events (in adults with LTBI).
[Analysis 1.10]
Analysis 1.10. Comparison 1 Rifampicin versus INH, Outcome 10 Any adverse event (in adults with silicosis).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Rifampicin plus INH versus INH, Outcome 1 Active TB: INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Rifampicin plus INH versus INH, Outcome 2 Drug-resistant TB.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Rifampicin plus INH versus INH, Outcome 3 Adherence.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Rifampicin plus INH versus INH, Outcome 4 Serious adverse events: INH plus rifampicin 3 months versus INH 9 months (in adults).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Rifampicin plus INH versus INH, Outcome 5 Treatment-limiting adverse events.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Rifampicin plus INH versus INH, Outcome 6 Hepatotoxicity.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Rifampicin plus INH versus INH, Outcome 7 Gastrointestinal intolerance.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Rifampicin plus INH versus INH, Outcome 8 Any adverse event: INH plus rifampicin 3 months versus INH 6 months (in adults with silicosis).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 1 Active TB.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 2 Drug-resistant TB.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 3 Adherence.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 4 Treatment-limiting adverse events (in adults).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 5 Hepatotoxicity.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 6 At least one adverse event (in adults).
[Analysis 3.7]
Analysis 3.7. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 7 Gastrointestinal Intolerance (in adults).
[Analysis 3.8]
Analysis 3.8. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 8 Rash (in adults).
[Analysis 3.9]
Analysis 3.9. Comparison 3 Rifampicin plus pyrazinamide versus INH, Outcome 9 Pruritus (in adults).
[Analysis 4.1]
Analysis 4.1. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 1 Active TB.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 2 All-cause mortality.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 3 Drug-resistant TB.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 4 Adherence.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 5 Serious adverse events.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 6 Treatment-limiting adverse events.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 7 Hypersensitivity.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 8 Hepatotoxicity.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 9 Rash.
[Analysis 4.10]
Analysis 4.10. Comparison 4 Rifapentine plus INH weekly for 3 months versus INH daily for 9 months, Outcome 10 Any adverse event.